Toyama/Eisai's iguratimod filed for RA in Japan
This article was originally published in Scrip
Executive Summary
Toyama Chemical and development partner Eisai have filed for the approval in Japan of iguratimod (T-614) as an add-on therapy for the treatment of rheumatoid arthritis (RA).